SGLT2 inhibitor luseogliflozin ameliorates glycemic control in db/db mice.
Luseogliflozin increases β-cell proliferation and decreases β-cell apoptosis.
Luseogliflozin preserves various β-cell-specific gene expression.
Luseogliflozin decreases various fibrosis-related factors in db/db mice.